Research programme: retinoic acid receptor gamma agonists - Locus Pharmaceuticals

Drug Profile

Research programme: retinoic acid receptor gamma agonists - Locus Pharmaceuticals

Alternative Names: RARγ agonists; RARγ agonists research programme - Locus Pharmaceuticals; Retinoic acid receptor gamma research programme - Locus Pharmaceuticals

Latest Information Update: 10 May 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Locus Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action Retinoic acid receptor gamma agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cervical cancer; Leukaemia

Most Recent Events

  • 25 Jul 2003 Preclinical development for Leukaemia in USA (unspecified route)
  • 25 Jul 2003 Preclinical development for Cervical cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top